Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript

SA Transcripts 161.55K Followers Follow Evolus, Inc. ( EOLS ) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDT Company Participants Nareg Sagherian - Head of Global Investor Relations & Corporate Communications David Moatazedi - President, CEO & Director Rui Avelar - Chief Medical Officer and Head of Research & Development Tatjana Mitchell - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Marc Goodman - Leerink Partners LLC, Research Division Navann Ty Dietschi - BNP Paribas, Research Division Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Sam Eiber - BTIG, LLC, Research Division John Gionco - Needham & Company, LLC, Research Division Presentation Operator Good afternoon, everyone, and thank you for standing by. Welcome to Evolus Second Quarter 2026 Earnings Call. [Operator Instructions] As a reminder, today's conference call is being recorded and webcast live. [Operator Instructions] I would now like to turn the conference over to Nareg Sagherian, Vice President and Head of Global Investor Relations and Corporate Communications. Please go ahead. Nareg Sagherian Head of Global Investor Relations & Corporate Communications Thank you, operator, and welcome to everyone joining us on today's call to review Evolus' second quarter financial results. Our second quarter press release is now available on the Investor Relations section of our website at evolus.com. Joining me on today's call are David Moatazedi, President and Chief Executive Officer; Rui Avelar, Chief Medical Officer and Head of R&D; and Tatjana Mitchell, Chief Financial Officer. Today's call will include forward-looking statements. Actual results may differ materially due to risks and uncertainties outlined in our earnings press release and SEC filings. These forward-looking statements are based on current assumptions, and we undertake no obligation to update them. Additionally, we will discuss certain non-GAAP financial measures. These measures should be considered in addition to and not as a substitute for our GAAP results. A